One in 14 Hospitalized Patients Face Harmful Diagnostic Errors
By Lori Solomon HealthDay Reporter
THURSDAY, Oct. 3, 2024 -- Harmful diagnostic errors (DEs) occur in an estimated one of every 14 hospitalized general medicine patients, according to a study published online Oct. 1 in BMJ Quality & Safety.
Anuj K. Dalal, M.D., from Brigham and Women’s Hospital in Boston, and colleagues assessed the prevalence of harmful DEs among hospitalized patients. The analysis included electronic medical record reviews for a random sampling of 675 patients with a transfer to the intensive care unit (ICU), death within 90 days, complex clinical events, and none of the high-risk criteria.
The researchers found that population estimates of harmful, preventable, and severely harmful DEs were 7.2 percent for ICU transfers, 6.1 percent for death within 90 days, and 1.1 percent for complex clinical events. More than six in 10 harmful DEs were characterized as delays (61.9 percent). In high-risk cases, severely harmful DEs were frequent (55.1 percent). Process failures in assessment, diagnostic testing, subspecialty consultation, patient experience, and history were significantly associated with harmful DEs.
"Patient safety research and institutional quality and safety programs should consider structured case reviews and novel approaches for improving detection of adverse DEs for hospitalized patients," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-04 06:00
Read more
- Just 5 Extra Minutes of Exercise Per Day Could Lower Blood Pressure
- Expanded Admission Screening Protocol for Candida Auris Beneficial
- Long-Term Upadacitinib Use Feasible for Adolescents With Atopic Dermatitis
- Prevalence of High Total Cholesterol 11.3 Percent in U.S. Adults
- AI Analysis of Video Can ID Neurologic Changes in the NICU
- Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions